Need professional-grade analysis? Visit stockanalysis.com
$1.47B
N/A
N/A
N/A
Nuvation Bio Inc (NUVB) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $5.11, up 0.59% from the previous close.
Over the past year, NUVB has traded between a low of $1.71 and a high of $9.54. The stock has gained 145.7% over this period. It is currently 46.4% below its 52-week high.
Nuvation Bio Inc has a market capitalization of $1.47B.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Side-by-side comparison against top Healthcare peers.